DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration announced today that it is approaching completion of patient enrollment of its U.S. Food and Drug Administration (FDA) pivotal study…
Category: Business
Aerie Pharmaceuticals to Present at the Canaccord Genuity Growth Conference
IRVINE, Calif., BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Canaccord Genuity Growth Conference on Wednesday, August 12, 2015 at 12:30 p.m. Eastern Time in Boston, MA. Dr. Anido’s presentation will include an Aerie overview and business update. The presentation will be webcast live and may be accessed by visiting A
Aerie Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Business Update
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2015 along with a general business update. Aerie Highlights Efficacy results from Aerie’s RhopressaTM Rocket 2 trial, using the primary clinical endp
Aerie Pharmaceuticals and GrayBug Announce Research Collaboration
IRVINE, Calif. & BALTIMORE–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degenera
Bruker Reports Second Quarter 2015 Financial Results
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today reported financial results for its second quarter ended June 30, 2015. Bruker’s revenues for the second quarter of 2015 were $396.0 million, a decline of 13.4 percent compared to the second quarter of 2014. Excluding a 2.6 percent negative effect from divestitures, and an 11.5 percent negative effect from changes in foreign exchange rates, Bruker reported year-over-year organic revenue growth of 0.7 percent in the second
European Pricing Platform® (EPP) and its forum partner, Alliance Life Sciences, announce the upcoming 5th EPP Life Sciences Pricing Forum, 21 – 23 September, Montreux.
BRUSSELS / SOMERSET, N.J.–(BUSINESS WIRE)–European Pricing Platform® (EPP) and its forum partner, Alliance Life Sciences, announce the upcoming 5th EPP Life Sciences Pricing Forum, 21 – 23 September, Montreux.
ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous sy…
Second Sight Reports Second Quarter 2015 Financial Results
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today reported financial results for the three-month period ended June 30, 2015. Second Quarter 2015 Highlights Grew net revenue by 335% to $2.7 million in the second quarter of 2015, compared to $0.6 million in the prior year period; Implanted 20 Argus® II s
Presbia Announces the Appointment of Marie Cha as Director of Direct Response Marketing
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration announced today the appointment of Marie Cha as Director of Direct Response Marketing. Ms. Cha brings extensive experience in consumer marketing, with a strong focus on digital platforms. Ms. Cha will be responsible for overseeing the development and expansion of direct response marketing for the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating pres
Eleven Biotherapeutics to Report Second Quarter 2015 Financial Results on August 13, 2015
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics will report second quarter 2015 financial results Thursday, August 13, 2015 and host a conference call and audio webcast at 8:30 a.m. ET that same day.
Ocular Therapeutix™ to Report Second Quarter 2015 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report se…
Presbia PLC Appoints Dr. Gerd Auffarth to the Board of Directors
DUBLIN–(BUSINESS WIRE)–The Board of Directors of Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration, announced today that it has appointed Dr. Gerd Auffarth, M.D., Ph.D. to the board. The board also announc…
Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the Second Quarter of 2015
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that it will host a conference call on Thursday, August 6, 2015 at 4:30 p.m. EDT, during which it will provide a corporate update for the second quarter of 2015. Interested parties may access the call live by dialing (888) 312-3054 (US) or (719) 325-2449 (international) and using conference ID 2737702. A live audio webcast of the presentation will b
NovaBay Pharmaceuticals to Hold Second Quarter 2015 Conference Call on August 13
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that it will report second quarter financial results after market close on Thursday, August 13. Management will hold an investment community conference call to discuss financial results and provide a company update. DATE: Thursday, August 13, 2015 TIME:
ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous sy…
Inotek Pharmaceuticals Announces Conversion of $21 Million Principal Amount of 5.0% Convertible Senior Notes due 2020
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that $20,970,000 of its 5.0% Convertible Senior Notes due 2020 (the “2020 Notes”) maturing February 15, 2020 have been converted into shares of common stock of the Company. The 2020 Notes converted into approximately 3.86 million shares, includ
Glaukos Corporation to Release Second Quarter 2015 Financial Results After Market Close on August 12
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release second quarter 2015 financial results after the market close on Wednesday, August 12, 2015. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on Au
Opternative Revolutionizes Eye Exams with Launch of Online, Ophthalmologist-Issued Prescription Service for Glasses and Contacts
CHICAGO–(BUSINESS WIRE)–Opternative, the world’s first online eye exam service, is now available to provide consumers with a convenient and affordable physician-issued prescription for glasses or contacts. By using a computer and smartphone, consumers can take a 25-minute or less eye exam from the comfort of home and receive a prescription within 24 hours to use at any online or neighborhood optical retailer. Opternative exams cost $40 for a prescription for glasses or contacts and $60 for bo
Research and Markets: Global Wet (Neovascular / Exudative) Macular Degeneration Pipeline Insights Report 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/rnv8jx/wet_neovascular) has announced the addition of the “Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Insights” report to their offering. Wet (Ne…
Visionworks and Davis Vision Launch ‘Let’s Go See’ – Children’s Eye Health Campaign to Raise Awareness of Importance of Annual Eye Exams
SAN ANTONIO–(BUSINESS WIRE)–Just in time for back-to-school, Visionworks and Davis Vision is launching ‘Let’s Go See,’ a cause marketing initiative focused on raising awareness about the importance of children receiving an annual eye exam. Reports from The Center for Health in Schools show that about 60% of students classified as problem learners have some sort of undetected visual problem. “Many parents take their children in for routine doctor and dental check-ups, but often wait for their